Amgen Inc. (NASDAQ:AMGN) Shares Acquired by O Brien Greene & Co. Inc

O Brien Greene & Co. Inc increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.4% during the 4th quarter, Holdings Channel reports. The fund owned 29,322 shares of the medical research company’s stock after purchasing an additional 1,224 shares during the quarter. Amgen makes up about 3.0% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 7th largest position. O Brien Greene & Co. Inc’s holdings in Amgen were worth $8,445,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Briaud Financial Planning Inc acquired a new stake in shares of Amgen in the third quarter valued at about $26,000. BOK Financial Private Wealth Inc. purchased a new stake in Amgen during the 4th quarter worth approximately $29,000. OFI Invest Asset Management purchased a new position in shares of Amgen in the third quarter valued at approximately $26,000. Planned Solutions Inc. purchased a new stake in shares of Amgen during the fourth quarter worth approximately $30,000. Finally, Providence Capital Advisors LLC acquired a new position in Amgen in the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.2 %

Shares of AMGN stock opened at $269.98 on Friday. The business’s fifty day moving average price is $275.10 and its 200 day moving average price is $281.45. The firm has a market capitalization of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.60 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. During the same period in the previous year, the firm posted $4.09 earnings per share. Amgen’s revenue was up 19.8% on a year-over-year basis. As a group, sell-side analysts forecast that Amgen Inc. will post 19.43 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 72.06%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Raymond James began coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. The Goldman Sachs Group increased their price target on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. UBS Group reduced their price objective on Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Morgan Stanley cut their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Finally, SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.